Efficacy of deucravacitinib and guselkumab in a patient with psoriasis who had experienced multiple failures of biologics: a case report

We report the successful use of combination therapy in a 69-year-old man with recalcitrant psoriasis, achieving clinically significant improvement with deucravacitinib and guselkumab after multiple failures with biologics. The selective inhibition of tyrosine kinase 2 by deucravacitinib, combined with the blockade of interleukin-23 by guselkumab, may have led to enhanced suppression of the T helper cell 17 inflammatory pathway. Further research is needed to define the efficacy and tolerance of such combination regimens in patients with severe, difficult-to-treat psoriasis.